MRD in the ITT population (N = 458)
| . | After induction . | After ASCT . | After consolidation . |
|---|---|---|---|
| Median 3 × 10−6sensitivity, n (%) | |||
| MRD undetectable | 132 (28.8) | 193 (42.1) | 207 (45.2) |
| MRD positive | 264 (57.6) | 167 (36.5) | 157 (34.3) |
| Missing* | 62 (13.5) | 98 (21.4) | 94 (20.5) |
| 10−4sensitivity, n (%) | |||
| MRD undetectable | 217 (47.4) | 287 (62.7) | 302 (65.9) |
| MRD positive | 179 (39.1) | 73 (15.9) | 62 (13.5) |
| Missing* | 62 (13.5) | 98 (21.4) | 94 (20.5) |
| . | After induction . | After ASCT . | After consolidation . |
|---|---|---|---|
| Median 3 × 10−6sensitivity, n (%) | |||
| MRD undetectable | 132 (28.8) | 193 (42.1) | 207 (45.2) |
| MRD positive | 264 (57.6) | 167 (36.5) | 157 (34.3) |
| Missing* | 62 (13.5) | 98 (21.4) | 94 (20.5) |
| 10−4sensitivity, n (%) | |||
| MRD undetectable | 217 (47.4) | 287 (62.7) | 302 (65.9) |
| MRD positive | 179 (39.1) | 73 (15.9) | 62 (13.5) |
| Missing* | 62 (13.5) | 98 (21.4) | 94 (20.5) |
The main cause of missing data was patient discontinuation (61 patients before ASCT, 13 patients before day 100 after ASCT, and 13 patients before the end of consolidation). Less frequent reasons were lack of appropriate sample at the central laboratory, test failure, and patient’s consent withdrawal.